Contents

Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)

August 1, 2016

Cohort study

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.

Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL.

Ophthalmology. 2016 Aug;123(8):1751-1761.
Full text | Metrics.

Main finding: Vision gains during the first 2 years of the CATT study were not maintained at 5 years.

 

  • Purpose: To describe outcomes 5 years after initiating treatment with bevacizumab or ranibizumab for neovascular age-related macular degeneration
  • Study type: Cohort study
  • Condition: CNV secondary to AMD

Participants: Active CNV secondary to AMD, VA 20/25-20/320

 

  • n=1107

 

Intervention:

 

Group 1: Intravitreal Ranibizumab 0.5mg monthly
Group 2: Intravitreal Bevacizumab 1.25mg monthly
Group 3: Intravitreal Ranibizumab 0.5mg PRN
Group 4: Intravitreal Bevacizumab 1.25mg PRN

Vision gains during the first 2 years were not maintained; at 5 years 50% of eyes had VA of 20/40 or better and 20% had VA of 20/200 or worse.

 

Mean change in VA was −3 letters from baseline and −11 letters from 2 years.

July 1, 2012

Clinical Trial

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.

Ophthalmology. 2012 Jul;119(7):1388-98.
Full text | Metrics.

Main finding: Ranibizumab and bevacizumab had similar effects on visual acuity over a 2-year period

 

  • Purpose: To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment.
  • Study type: Randomized controlled trial
  • Condition: CNV secondary to AMD

Participants: Active CNV secondary to AMD, VA 20/25-20/320

 

  • n=1107

 

Intervention:

 

Group 1: Intravitreal Ranibizumab 0.5mg monthly
Group 2: Intravitreal Bevacizumab 1.25mg monthly
Group 3: Intravitreal Ranibizumab 0.5mg PRN
Group 4: Intravitreal Bevacizumab 1.25mg PR

Mean gain in VA was similar for both drugs (5.0-8.8 letters, bevacizumab-ranibizumab difference = −1.4 letters].

 

Mean VA gain was greater for monthly than for as-needed treatment (difference = −2.4 letters)

 

Rates of death and arteriothrombotic

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed